IDG 16177
Alternative Names: IDG-16177Latest Information Update: 28 Aug 2024
At a glance
- Originator Ildong Pharmaceutical
- Developer Evotec SE; Ildong Pharmaceutical
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Beta-arrestin stimulants; FFAR1 protein stimulants; Gastrointestinal hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Combination therapy) in Germany (PO)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Germany (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (PO)